LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
LENZ Therapeutics, Inc.
NASDAQ:LENZHealthcare · Biotechnology
-12.61%$3.05
AH$3.09+1.31%vs close
Mkt Cap$95.83M
Float–
O/S31.42M
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
Financials Summary
Revenue$19.09M
Net Income-$82.13M
Total Assets$305.88M
Free Cash Flow-$70M
Debt & Equity
Debt 0%
Equity 100%
Total Debt$815K
Total Equity$284.34M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
- 1:7Reverse splitMar 22, 20247 shares → 1
Balance Sheet Details
Assets$305.88M
Liabilities$21.54M
Accounts Receivable$2.43M
Accounts Payable$4.17M
Inventory$0
PP&E (Net)$1.92M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $19.09M | $0 | $0 | $15M | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - |
| Cost of Revenue | $705K | $58K | $0 | $0 | $734K | $121K | $0 |
| Gross Profit | $18.38M | -$58K | $0 | $15M | -$734K | -$121K | $0 |
| Gross Margin | 96.3% | - | - | 100.0% | - | - | - |
| Research and Development | $18.67M | $29.8M | $59.5M | $21.13M | $37.93M | $9.12M | $0 |
| Selling, General, and Administrative | $90.85M | $28.75M | $12.93M | $4.36M | $21.78M | $4.26M | $29K |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $109.52M | $58.55M | $72.43M | $25.48M | $59.71M | $13.38M | $29K |
| Operating Income (EBIT) | -$91.14M | -$58.61M | -$72.43M | -$10.48M | -$60.44M | -$13.5M | -$29K |
| Operating Margin | -477.5% | - | - | -69.9% | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $40K | $80K |
| Interest Income | $9.76M | $8.55M | $2.19M | $0 | $0 | $0 | $0 |
| Other Income (Expense) | $9.51M | $8.84M | $2.28M | $19K | -$10.32M | -$54.87M | -$80K |
| Income Before Tax (EBT) | -$81.63M | -$49.77M | -$70.15M | -$10.46M | -$70.76M | -$68.37M | -$109K |
| Income Tax Expense | $502K | $1K | -$179K | $347K | $0 | $0 | $0 |
| Net Income | -$82.13M | -$49.77M | -$69.97M | -$10.81M | -$70.76M | -$68.37M | -$109K |
| Net Income Margin | -430.3% | - | - | -72.1% | - | - | - |
| Supplementary Data | |||||||
| EPS | -2.85 | -2.34 | -15.30 | -12.89 | -8.54 | -8.24 | -0.01 |
| Diluted EPS | -2.85 | -2.34 | -15.30 | -12.89 | -8.54 | -8.24 | -0.01 |
| Weighted Average OS | 28.81M | 21.28M | 8.15M | 7.84M | 8.29M | 8.30M | 8.30M |
| EBITDA | -$81.34M | -$49.71M | -$70.13M | -$10.46M | -$70.03M | -$68.21M | $143K |
| EBITDA Margin | -426.1% | - | - | -69.7% | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $25.18M | $20.16M | $35.14M | $44.44M | $18.31M | $19.82M | $6K |
| Short-Term Investments | $267.17M | $188.87M | $30.65M | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $292.35M | $209.03M | $65.79M | $44.44M | $18.31M | $19.82M | $6K |
| Accounts Receivable | $2.43M | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $6.64M | $114K | $1.45M | $2.2M | $16K | $1.29M | $0 |
| Total Current Assets | $301.41M | $211.92M | $67.24M | $46.64M | $18.32M | $21.1M | $6K |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $1.92M | $1.99M | $372K | $279K | $10K | $1.46M | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $2.54M | $1.4M | $2.76M | $31K | $2K | $0 | $0 |
| Total Long-Term Assets | $4.46M | $3.39M | $3.13M | $310K | $12K | $1.46M | $0 |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $305.88M | $215.3M | $70.38M | $46.95M | $18.34M | $22.56M | $6K |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $4.17M | $4.26M | $5.71M | $4.75M | $460K | $630K | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $2.21M |
| Current Income Tax Payable | $0 | $0 | $0 | $347K | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $0 | $0 | $0 | $0 | $0 | $30.95M | $19K |
| Total Current Liabilities | $21.19M | $10.41M | $18.51M | $9.5M | $1.25M | $32.05M | $2K |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $144.38M | $61.47M | $31.3M | $316K | $0 |
| Total Long-Term Liabilities | $350K | $814K | $144.57M | $61.62M | $31.3M | $316K | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $21.54M | $11.22M | $163.09M | $71.12M | $32.55M | $32.36M | $2.22M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $55.61M | $0 |
| Common Stock | $1K | $1K | $10K | $10K | $1K | $0 | $0 |
| Retained Earnings | -$227.14M | -$145.01M | -$95.25M | -$25.28M | -$14.47M | -$70.59M | -$2.22M |
| Comprehensive Income & Other | $242K | $196K | $6K | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $511.48M | $349.1M | $2.52M | $1.1M | $251K | $60.79M | $0 |
| Total Equity | $284.34M | $204.08M | -$92.71M | -$24.17M | -$14.21M | -$9.8M | -$2.22M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $305.88M | $215.3M | $70.38M | $46.95M | $18.34M | $22.56M | $6K |
| Supplementary Data | |||||||
| Total Debt | $815K | $1.38M | $329K | $250K | $0 | $0 | $2.21M |
| Net Debt | -$24.36M | -$18.78M | -$34.81M | -$44.19M | -$18.31M | -$19.82M | $2K |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$82.13M | -$49.77M | -$69.97M | -$101.05M | -$70.76M | -$68.37M | -$109K |
| Depreciation & Amortization | $287K | $58K | $15K | $8K | $734K | $121K | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $12.55M | $6.37M | $1.34M | $0 | $0 | $0 | $0 |
| Changes in Working Capital: | |||||||
| Accounts Receivable | -$329K | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | -$4.28M | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$90K | -$4.28M | $856K | $194K | $1.82M | $594K | -$12K |
| Other Working Capital | $7.95M | -$8.81M | $8.55M | -$7.4M | -$4.32M | $1.11M | $22K |
| Total Working Capital Change | $3.25M | -$13.09M | $9.41M | -$7.21M | -$2.5M | $1.71M | $10K |
| Other Non-Cash Items | -$3.13M | -$2.95M | -$1.18M | $20.27M | $19.67M | $57.82M | $80K |
| Net Cash from Operating | -$69.17M | -$59.39M | -$60.38M | -$87.98M | -$52.85M | -$8.72M | -$19K |
| Investing Activities | |||||||
| Capital Expenditures | -$827K | -$468K | -$30K | -$6.59M | -$5.74M | -$1.54M | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$280.8M | -$241.91M | -$52.09M | -$405.52M | $0 | $0 | $0 |
| Sales of Investments | $205.96M | $87.9M | $22.5M | $170.25M | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$75.67M | -$154.48M | -$29.62M | -$241.86M | -$5.74M | -$1.54M | $0 |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | - | - | - | - |
| Common Stock Issuance | $149.75M | $79.51M | $203K | $676K | $417.16M | $30.08M | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | -$79K | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $119.49M | -$2.48M | $0 | $306K | $0 | $0 |
| Net Cash from Financing | $149.75M | $199M | $80.7M | $597K | $417.47M | $30.08M | $0 |
| Forex Effect | $0 | $0 | $0 | $0 | -$1.72M | $0 | $25K |
| Net Change in Cash | $4.91M | -$14.87M | -$9.3M | -$329.25M | $357.16M | $19.81M | $6K |
| Supplementary Data | |||||||
| Operating Cash Flow | -$69.17M | -$59.39M | -$60.38M | -$87.98M | -$52.85M | -$8.72M | -$19K |
| Capital Expenditure | -$827K | -$468K | -$30K | -$6.59M | -$5.74M | -$1.54M | $0 |
| Free Cash Flow | -$70M | -$59.86M | -$60.41M | -$94.57M | -$58.59M | -$10.27M | -$19K |
| Cash at Beginning | $20.27M | $35.14M | $44.44M | $376.98M | $19.82M | $6K | $0 |
| Cash at End | $25.18M | $20.27M | $35.14M | $47.73M | $376.98M | $19.82M | $6K |